Filippo de Marinis

机构：European Institute of Oncology · ORCID：0000-0002-1118-5536

发表论文 727 篇 · 总被引 48115 次 · h-index 81

代表论文

• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 110)
• Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial (2025 · The Lancet · 被引 50)
• Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study (2025 · Annals of Oncology · 被引 42)
• First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. (2025 · Journal of Clinical Oncology · 被引 22)
• HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top (2025 · Molecules · 被引 20)
• Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List (2025 · Cancers · 被引 12)